reviewThe Lancet OncologyJul 23, 2011Closed access

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Beth Israel Deaconess Medical Center · Harvard University

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

598
total citations
FWCI
28.35
Percentile
100%
References
80
Citations per year

Authors

3

Topics & keywords

Keywords
  • Gefitinib
  • Afatinib
  • Exon
  • Erlotinib
  • Neratinib
  • Epidermal growth factor receptor
  • Lung cancer
  • Cancer research
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding